Accessibility Menu
 
Cytek Biosciences logo

Cytek Biosciences

(NASDAQ) CTKB

Current Price$4.59
Market Cap$581.05M
Since IPO (2021)-76%
5 YearN/A
1 Year+22%
1 Month+7%

Cytek Biosciences Financials at a Glance

Market Cap

$581.05M

Revenue (TTM)

$201.49M

Net Income (TTM)

$66.54M

EPS (TTM)

$-0.52

P/E Ratio

-8.70

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$4.59

Volume

19,702

Open

$4.51

Previous Close

$4.59

Daily Range

$4.43 - $4.63

52-Week Range

$2.37 - $6.18

CTKB News

CTKB: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cytek Biosciences

Industry

Life Sciences Tools and Services

Employees

700

CEO

Wen Bin Jiang, PhD

Headquarters

Fremont, CA 94538, US

CTKB Financials

Key Financial Metrics (TTM)

Gross Margin

52%

Operating Margin

-20%

Net Income Margin

-33%

Return on Equity

-18%

Return on Capital

-11%

Return on Assets

-14%

Earnings Yield

-11.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$581.05M

Shares Outstanding

128.55M

Volume

19.70K

Short Interest

0.00%

Avg. Volume

816.61K

Financials (TTM)

Gross Profit

$104.46M

Operating Income

$40.38M

EBITDA

$17.39M

Operating Cash Flow

$4.69M

Capital Expenditure

$4.08M

Free Cash Flow

$8.77M

Cash & ST Invst.

$261.53M

Total Debt

$33.02M

Cytek Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$62.14M

+8.1%

Gross Profit

$32.88M

-2.3%

Gross Margin

52.92%

N/A

Market Cap

$581.05M

N/A

Market Cap/Employee

$876.39K

N/A

Employees

663

N/A

Net Income

$44.08M

-557.1%

EBITDA

$263.00K

+89.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$228.50M

-12.4%

Accounts Receivable

$72.13M

+19.0%

Inventory

$0.00

-100.0%

Long Term Debt

$21.35M

+148.2%

Short Term Debt

$11.67M

+38.7%

Return on Assets

-14.42%

N/A

Return on Invested Capital

-10.52%

N/A

Free Cash Flow

$1.77M

-262.0%

Operating Cash Flow

$771.00K

-138.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SRDXSurmodics, Inc.
$42.98+0.35%
AVNSAvanos Medical, Inc.
$13.69-1.01%
CBLLCeriBell, Inc.
$17.87-1.65%
VREXVarex Imaging Corporation
$10.59+0.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.49-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$44.15+0.00%
NOKNokia
$8.85-0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.25-0.01%

Questions About CTKB

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.